|本期目录/Table of Contents|

[1]周蕾,王茜,李丹丹,等.Tenovin-6 对AML1/ETO （+） 急性髓系白血病细胞的增殖抑制和促凋亡作用[J].慢性病学杂志,2015,(02):150-154.
　ZHOU Lei*,WANG Qian,LI Dan-dan,et al.Effects of a histone deacetylase inhibitor, tenovin-6, against cellular proliferation and promoting apoptosis in AML1-ETO-positive acute myeloid leukemia cells[J].,2015,(02):150-154.
点击复制

Tenovin-6 对AML1/ETO （+） 急性髓系白血病细胞的增殖抑制和促凋亡作用(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2015年02期
页码:
150-154
栏目:
论著
出版日期:
2015-04-30

文章信息/Info

Title:
Effects of a histone deacetylase inhibitor, tenovin-6, against cellular proliferation and promoting apoptosis in AML1-ETO-positive acute myeloid leukemia cells
作者:
周蕾1; 2;  王茜1;  李丹丹1;  张晓东2;  王立军1;  王莉莉1;  于力1;  窦立萍1
1. 解放军总医院血液科，北京100853；2. 解放军第二○ 二医院血液科，沈阳110083
Author(s):
ZHOU Lei*;  WANG Qian;  LI Dan-dan;  ZHANG Xiao-dong;  WANG Li-jun;  WANG Li-li;  YU Li;  DOU Li-ping
*Department of hematology, Chinese PLA General Hospital, Beijing 100853, China Corresponding author: DOU Li-Ping, E-mail: lipingruirui@163.com
关键词:
组蛋白去乙酰化酶抑制剂; Tenovin-6; AML1/ETO; 急性髓系白血病; 细胞增殖; 细胞凋亡
Keywords:
Histone deacetylase inhibitor;  Tenovin-6;  AML1-ETO fusion protein;  Acute myeloid leukemia;  Cellular proliferation;  Apoptosis
分类号:
R587.24
DOI:
-
摘要:
目的观察组蛋白去乙酰化酶抑制剂(HDACi)Tenovin- 6 对人AML1/ETO （+） 急性髓系白血病 (AML)细胞的增殖、细胞凋亡及周期的影响。方法用CCK- 8 法及克隆形成试验检测Tenovin- 6 对 AML1/ETO （+） AML 细胞增殖活性的影响；流式细胞仪检测不同浓度Tenovin-6 作用于细胞后细胞凋 亡、细胞周期的变化；并与AML1/ETO （－） AML 细胞系进行比较。结果Tenovin-6 对AML1/ETO （+） AML 细胞有增殖抑制作用， 其抑制作用呈现为时间和浓度依赖性， 并使细胞克隆形成能力下降； Tenovin-6 可以促进AML1/ETO （+） AML 细胞凋亡，并诱导细胞周期阻滞于G1 期，表现为G1 期细胞比 例升高，而G2/M 及S 期细胞比例下降，且与AML1/ETO （-） AML 细胞系相比较具有更高的敏感性。 结论Tenovin-6 能抑制AML1/ETO （+） AML 细胞增殖， 诱导细胞凋亡， 使周期阻滞于G1 期， 并较 AML1/ETO （－） AML 细胞系具有更高的敏感性。
Abstract:
Objective To investigate the effects of Tenovin- 6, a sort of Histone Deacetylase Inhibitor (HDACi), on the proliferation, apoptosis and cell cycles of AML1-ETO-Positive Acute Myeloid Leukemia (AML) cells. Methods Cell proliferation was measured by Cell Counting Kit- 8 (CCK- 8) and Clonality Assays. Both cell apoptosis and cell cycles were analyzed using Flow Cytometry method. Results were compared to AML1-ETO-Negtive AML cells. Results Tenovin-6 inhibited cellular proliferation in a time-dependent and dose-dependent manner in vitro and reduced colony formation. Tenovin- 6 induced apoptosis in AML1-ETO-Positive AML cell lines and evoked partial cell cycles arresting in G1 phase, which included the accumulation of cell rates in G1 phase and reduction of cell rates in G2/M phase and S phase. AML1- ETO- Positive AML cells were more sensitive to Tenovin- 6 doses than AML1- ETO- Negtive AML cells. Conclusions Tenovin- 6 could inhibit cellular proliferation, evoke partial cell cycle arresting in G1 phase, and induce apoptosis in AML1-ETO-Positive AML cell lines and have more effects compared to AML1-ETO-Negtive AML cells.

参考文献/References:

[1] Grisolano JL, O'Neal J, Cain J, et al. An activated receptor ty? rosine kinase, TEL/PDGFbetaR, cooperates with AML1- ETO to induce acute myeloid leukemia in mice ［J］． Proc Natl Acad Sci U S A, 2003,100(16):9506-9511.
[2］ Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cuta? neous T- cell lymphoma (CTCL) ［J］． Blood, 2007,109(1): 31-39.
[3］ Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T- cell lymphoma ［J］．J Clin Oncol, 2007,25(21):3109-3115.
[4］ Jang KY, Hwang SH, Kwon KS, et al. SIRT1 expression is associated with poor prognosis of diffuse large B- cell lympho? ma ［J］．Am J Surg Pathol, 2008,32(10):1523-1531.
[5］ Yuan H, Wang Z, Li L, et al. Activation of stress response gene SIRT1 by BCR- ABL promotes leukemogenesis ［J］． Blood, 2012,119(8):1904-1914.
[6］ Sasca D, Hahnel PS, Szybinski J, et al. SIRT1 prevents geno? toxic stress- induced p53 activation in acute myeloid leukemia ［J］．Blood, 2014,124(1):121-133.
[7］ Wang Z, Yuan H, Roth M, et al. SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells ［J］． Oncogene, 2013,32(5):589-598.
[8］ 王茜, 窦立萍, 李永辉,等.SIRT1 启动子表达调控载体的构建 和活性分析及AML1-ETO 对其转录活性的影响［J］．中国 实验血液学杂志,2015. 23(1):12-18.
[9］ Lin RJ, Nagy L, Inoue S, et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia ［J］． Nature, 1998,391:811–814.
[10］ Gelmetti V, Zhang J, Fanelli M, et al. Aberrant recruitment of the nuclear receptor corepressor– histone deacetylase complex by the acute myeloid leukemia fusion partner ETO ［J］． Mol Cell Biol, 1998,18(12):7185–7191.
[11］ Martens JH, Brinkman AB, Simmer F, et al. PML- RARal? pha/RXR alters the epigenetic landscape in acute promyelocyt? ic leukemia ［J］．Cancer Cell, 2010,17(2):173–185.
[12］ Li L, Wang L, Li L, et al. Activation of p53 by SIRT1 inhibi? tion enhances elimination of CML leukemia stem cells in com ? bination with imatinib ［J］．Cancer cell, 2012,21(2):266-281.

备注/Memo

备注/Memo:
基金项目： 国家自然科学基金资助项目( 30800482， 81270610， 81170518， 30971297 )； 北京市科技新星计划项目 (2011114 )；北京市自然科学基金资助项目（7132217）；军队高新技术项目（2010gxjs091） 作者简介： 周蕾，硕士，主治医师，从事白血病诊治研究 通信作者： 窦立萍，E-mail: lipingruirui@163.com
更新日期/Last Update: 2015-04-15